IASIS PHARMA is pleased to announce the launch of Sitagliptin/IASIS 25 mg/mL in the pharmaceutical form of an oral solution.

This is a new, innovative, and unique formulation belonging to the class of DPP-4i. It is an R&D and manufacturing product by IASIS PHARMA HELLAS.

Each 1 mL of Sitagliptin/IASIS oral solution contains sitagliptin hydrochloride monohydrate, equivalent to 25 mg of sitagliptin.

Superior to Solid Dosage Forms & Optimal Adhearence:

Sitagliptin/IASIS 25 mg/mL oral solution represents an excellent therapeutic option, specifically designed for patients facing swallowing difficulties (dysphagia). It provides patients with type 2 diabetes mellitus with rapid bioavailability, high dosing accuracy, ease of titration, and optimal treatment compliance.

Dosage and Administration :

The recommended dose is 100 mg (corresponding to 4 mL of oral solution) of sitagliptin once daily, taken with or without food. The solution is slightly opalescent, off-white, featuring a pleasant wild berry aroma.

Suitable for Special Patient Populations (Renal Impairment):

According to the Summary of Product Characteristics (SPC), no dose adjustment is required for patients with mild or moderate renal impairment (GFR ≥ 45 mL/min). For patients with GFR ≥ 30 to < 45 mL/min, the dose is adjusted to 50 mg (2 mL of solution) once daily, while for severe renal impairment (GFR < 30 mL/min), the dose is 25 mg (1 mL of solution) once daily.

Packaging & Ease of Use:

Sitagliptin/IASIS is supplied in an amber glass bottle. To ensure maximum dosing accuracy and convenience during administration, the pack includes a 5 mL graduated plastic syringe in 0.5 mL increments.

Athenaeum InterContinental, Athens

During 19 – 23/11 2025, at Athenaeum InterContinental / Athens, the Hellenic Dermatology & Venereology Society together with the Dermatology & Venereology Society of Cyprus organized the 3^rd Panhellenic Conference of Dermatology and Venerology.

Greek Dermatologists who attended the congress visited IASIS PHARMA exhibition stand to get informed of the IASIS Dermatological products:

• Isotroin^®/ Isotretinoin, indicated for severe forms of Acne that are resistant to treatment with systemically administered antibiotics and topical therapy. Isotroin^® 30mg is added to the range of the other Isotroin® strengths (10mg, 20mg & 40mg).
• Combi^®, a combination of fluprednidene (1mg) + miconazole (20mg) cream for the treatment of Inflammatory Dermatomycoses.
• Modiwart^®/Ιmiquimod (12,5mg/sach), an innovative modifier of the immune response system indicated for the treatment of: External Genital Warts, Superficial Basal Cell Carcinomas and Aktinic Keratoses.
• Mastiha var. Chia Cutaneous Regenerative Gel (30ml), which is used in minor skin inflammations and as an aid in the healing of microtraumas, because since 2015, Chios mastic gum has been officially recognized by the European Medicines Agency (EMA) as Herbal Medicine with the indication: Skin Inflammation & Skin Wound Healing (cutaneous use).

Grand Hyatt/Athens

IASIS PHARMA participated in the “24^th PANHELLENIC CONGRESS OF HYPERTENSION” which was held from 07/11 to 09/11 2024, at the Grand Hyatt Hotel/Athens.

The conference was organized by the Hellenic Society of Hypertension (HSH).

IASIS PHARMA presented at its exhibition stand the following products:

•  RosuZet^®: New Product Launching. Fixed-dose combination of Rosuvastatin & Ezetimibe, in a single dosage form, in packages of 30 f.c. tabs available in the full spectrum of strengths:(Rosuvastatin / Ezetimibe) 5 / 10mg, 10 / 10mg, 20 / 10mg, 40 / 10mg.
• Rami–Amlo^®: Ramipril & Amlodipine, the original fixed dose combination of angiotensin-converting enzyme inhibitors with calcium channel blockers. Therapeutic indication, substitution therapy in patients whose blood pressure is adequately controlled with ramipril and amlodipine simultaneously at the same dose level. (Box of 28 caps, Ramipril / Amlodipine: 5mg / 5mg, 5mg / 10mg, 10mg / 5mg, 10mg / 10mg).
• Rami–Amlo plus^®/ the original fixed dose combination of Ramipril – Amlodipine – Hydrochlorothiazide, indicated for the treatment of Hypertension. (Box of 30 caps, Ramipril / Amlodipine / Hydrochlorothiazide: 5 mg / 5 mg / 12,5 mg, 5 mg / 5 mg / 25 mg, 10 mg / 5 mg / 25 mg, 10 mg / 10 mg / 25 mg).

RosuZet® is the fixed dose combination of Rosuvastatin – Ezetimibe, two active ingredients that reduce serum lipid levels with complementary mechanisms of action. Pharmacotherapeutic Class: Lipid Modifying Agents, HMG CoA reductase inhibitors in combination with other lipid modifying agents.

RosuZet® is indicated as an adjunct therapy to the diet for the treatment of primary hypercholesterolemia for adult patients adequately controlled with the drugs administered individually at the same dose level.

RosuZet®, as a fixed dose combination is indicated to reduce the risk of cardiovascular events as therapy for patients with coronary heart disease (CHD) and history of acute coronary syndrome (ACS), who are adequately controlled with individual agents administerted individually at the same dose.

It is available in packs of 30 film-coated tablets and in a wide dosage range:

• RosuZet® F.C.TAB (5+10)mg
• RosuZet® F.C.TAB (10+10)mg
• RosuZet® F.C.TAB (20+10)mg
• RosuZet® F.C.TAB (40+10)mg

The active substance of Zylapour^® is Allopurinol.

Allopurinol is in the class of medications called xanthine oxidase inhibitors and it was approved for medical use in the United States in 1966. It is included in the World Health Organization’s List of Essential Medicines.

Zylapour^® as an once-daily single tablet regimen, is the ideal Treatment of Primary and Secondary Hyperuricemia and the Prevention of its Complications, mainly for the Prophylaxis against Gout (primary, secondary)as well as Uric Acid Nephrolithiasis.

Dr. Christos Kon. Zavos, Gastroenterologist – Hepatologist introduced the product to PharmaQ sales force at the new facilities of Iasis Pharma in Koropi.

Dr. Christos Kon. Zavos presented all the Updated Facts, Important Scientific Data & Newest Developments regarding this unique herbal medicine [E.M.A. 2015], the Mastiha var.Chia caps and the wide range of beneficial therapeutic indications for humans, mainly against functional dyspepsia, with the active substance the natural Mastic of Chios (Pistacia lentiscus var chia), of 350mg.

Chios Mastiha Powder has all the beneficial properties of Mastiha var.Chia. Available in a practical 1080mg single-dose sachet pack, the tritated fixed dose of Mastic Gum is easily carried and taken with yogurt or other food.

• Ideal for those who have difficulty swallowing a solid dose (dysphagia).
• Compared to solid oral dosage forms, such as tablets, capsules, capsules with pearls, Chios Mastiha Powder is easier to be taken, especially by the elderly and children.

– Daily dosage: 1 sachet of Mastic Chios Powder.

– Chios Mastiha Powder does not contain preservatives, artificial colors, fragrances, or allergenic ingredients.

– Gluten & Lactose Free.

It is distributed in pharmacies by Pharma Q S.A. an Iasis Pharma company, Tel.: (+30) 2109374576

Qpain^® is a new topical anti-inflammatory cutaneous solution, containing diclofenac sodium 1.5% w/w, indicated for the symptomatic relief of pain associated with osteoarthritis in superficial joints, including the knee.

– Qpain^® contains DMSO which enhances the absorption of diclofenac from the skin and reaches the focus of pain and inflammation directly.

• Ideal for those who cannot take oral medication.
• Excellent safety profile.
• Easy patient compliance.

Available in a 30ml package

Dosage: apply 20 to 40 drops four times daily to each joint or due to your physician instructions.

Distributed in pharmacies by:

PharmaQ S.A. an IASIS PHARMA company – tel. 210 9374576, www.pharmaq.gr

This Innovative Pharmaceutical Form is a global market leader. This dosage form is Research and Development by IASIS PHARMA HELLAS S.A.

Each 5ml of oral suspension Nitrofurantoin/IASIS oral susp. contains 25mg of Nitrofurantoin monohydrate which, according to international literature, is the 1st Choice in the Global Guidelines for the Prevention & Treatment of Uncomplicated UTIs.

Nitrofurantoin/IASIS oral susp. is available in the market in the two pack sizes of 150ml & 300ml respectively, indicated mainly for the treatment & prophylaxis against acute or recurrent, uncomplicated lower urinary tract infections or pyelitis, either spontaneous or after surgical operations. It is specifically indicated for the treatment of infections caused by resistant strains of Escherichia coli, Enterococci, Staphylococci, Citrobacter, Klebsiella and Enterobacter.

Nitrofurantoin/IASIS oral susp. is indicated for use in adults and children over three months of age.

It is promoted by PharmaQ, a company of IASIS PHARMA HELLAS S.A.

ETROZAC® active substance is etoricoxib which is a selective cox-2 inhibitor.

ETROZAC® is indicated for the relief of the symptoms of Osteoarthritis (OA), Rheumatoid Arthritis (RA), Ankylosing Spondylitis and the pain and symptoms of inflammation associated with Acute Gout. ETROZAC® is indicated for the short-term treatment of moderate pain associated with dental surgery.

ETROZAC® is available in packages of 14 or 20 film-coated tablets, in a wide dosage range:

Etrozac® 20 tabs x 60 mg
Etrozac® 14 tabs x 90 mg
Etrozac® 20 tabs x 90 mg
Etrozac® 20 tabs x 120 mg

Rami – Amlo plus® is an original (prototype) fixed dose combination of Ramipril – Amlodipine -Hydrochlorothiazide

Rami – Amlo plus® is indicated for the treatment of hypertension.

Available in packs of 30 capsules, in a wide dosage range:

Rami – Amlo plus^®, 5 mg / 5 mg / 12,5 mg (Ramipril / Amlodipine / Hydrochlorothiazide)
Rami – Amlo plus^®, 5 mg / 5 mg / 25 mg
Rami – Amlo plus^®, 10 mg / 5 mg / 25 mg
Rami – Amlo plus^®, 10 mg / 10 mg / 25 mg